8-K: Oncocyte Secures $15.8 Million in Private Placement to Bolster Operations and Redeem Preferred Stock

Oncocyte Corporation has successfully raised $15.8 million through a private placement to fund operations and redeem outstanding preferred stock.

Summary

• Oncocyte Corporation has entered into agreements for a private placement, selling 5,077,387 shares of common stock at $2.9164 per share.
• The company also issued pre-funded warrants to purchase 342,888 shares at $2.9163 per warrant, with an exercise price of $0.0001 per share.
• The private placement, priced at-the-market under Nasdaq rules, is expected to close around April 15, 2024.
• Gross proceeds from the placement are estimated at $15.8 million before fees and expenses.
• The company plans to use the net proceeds for general corporate purposes, working capital, and to redeem approximately $5 million of outstanding Series A Preferred Stock.
• Needham & Company served as the exclusive placement agent for this transaction.
• The company has agreed to file a registration statement with the SEC for the resale of the shares and underlying warrants within 60 days, aiming for effectiveness within 75 days if a full SEC review is required.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a successful capital raise and strategic use of funds. However, the dilution risk and the need to redeem preferred stock temper the overall sentiment.

Positives

• The private placement provides a significant capital infusion of $15.8 million.
• The funds will be used to strengthen the company's balance sheet and support ongoing operations.
• The redemption of Series A Preferred Stock will simplify the company's capital structure.
• The at-the-market pricing under Nasdaq rules suggests a fair valuation of the securities.
• The company has a clear plan for the use of proceeds, including working capital and general corporate purposes.

Negatives

• The private placement will result in dilution of existing shareholders' equity.
• The company will incur placement agent fees and other offering expenses, reducing the net proceeds.
• The company is required to file a registration statement for the resale of the securities, which may take time and resources.
• The company is required to redeem the Series A Preferred Stock on April 15, 2024, which may put pressure on cash flow.

Risks

• The private placement is subject to customary closing conditions, which may not be satisfied.
• The company's ability to achieve its business objectives depends on the successful use of the net proceeds.
• The company's stock price may be negatively impacted by the dilution resulting from the private placement.
• The company's ability to have the registration statement declared effective by the SEC is not guaranteed.
• The company's future financial performance is subject to various risks and uncertainties.

Future Outlook

The company intends to use the net proceeds for general corporate purposes, working capital, and to redeem outstanding Series A Preferred Stock. The company also plans to file a registration statement for the resale of the securities.

Management Comments

• In 2023, we made significant progress on cost controls and in the development of our transplant monitoring IP, said Josh Riggs, CEO of Oncocyte.
• We continue to benefit from strong support from our core investors and welcome new ones in our recently completed $15.8MM private placement offering.
• With this partnership and financing we believe that we are well-positioned to meet our critical commercial and regulatory milestones.

Industry Context

This private placement is a common method for biotech companies to raise capital, especially when they need to fund ongoing operations and development. The at-the-market pricing suggests the company is trying to raise capital without significantly impacting the market price of its stock.

Comparison to Industry Standards

• The use of a private placement to raise capital is a standard practice in the biotech industry, particularly for companies that are not yet profitable.
• The pricing of the offering at-the-market is a common approach to minimize the impact on the stock price.
• The use of pre-funded warrants is a mechanism to allow investors to participate in the offering while managing their ownership limits.
• The company's plan to use the proceeds for working capital and to redeem preferred stock is typical for companies in this stage of development.
• Comparable companies that have recently raised capital through private placements include [insert comparable companies if known], which have also used similar structures and pricing mechanisms.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company's financial position will be strengthened by the capital raise.
• The company will be able to redeem outstanding Series A Preferred Stock.
• The company will have additional working capital to support its operations and growth.

Next Steps

• The company will close the private placement on or about April 15, 2024.
• The company will file a registration statement with the SEC for the resale of the securities within 60 days.
• The company will use the net proceeds for working capital, general corporate purposes, and to redeem outstanding Series A Preferred Stock.

Key Dates

Keywords

private placement, common stock, pre-funded warrants, capital raise, Series A Preferred Stock, working capital, registration statement, at-the-market, Needham & Company, dilution